




[図1]




[図2]

Fig.2




[図3]

Fig.3




[図4]

Fig.4




[図5]

Fig.5




[図6]

Fig.6




[図7]

Fig.7




[図8]


各個体における投与スケジュール




[図9A]



[図9B]




[図10]




[図11A]

抗HIV薬休薬後のSHIV89.6P感染カニクイザル(#137)のウイルス量およびCD4+T細胞




[図11B]

抗HIV薬休薬後のSHIV89.6P感染カニクイザル(#139)のウイルス量およびCD4+T細胞




[図12]




[図13]

SHIV89.6P接種カニクイザルにおける抗HIV薬投与後のウイルス量




⇒ ウイルス接種後、各個体のウイルス動態に大きな差は無い

[図14]



[図15]



[図16]

